Amicare Sp. z o.o. S.K.

At Amicare Sp. z o.o. S.K., investigators are evaluating new oral and injectable agents to induce remission in patients with Ulcerative Colitis and Crohn's Disease, aiming to reduce symptoms and improve intestinal healing.

• Oral NX-13 as a novel therapy for ulcerative colitis
• Duvakitug induction regimen for moderate to severe ulcerative colitis
• Duvakitug induction regimen for moderate to severe Crohn's disease
• Oral mesalazine formulation for active mild to moderate ulcerative colitis

The site in Jelenia Góra conducts four active studies with three investigators, focusing on innovative treatment options for inflammatory bowel disorders.

Research at this hospital explores modulation of the immune response in conditions such as immune system diseases, with a particular emphasis on achieving clinical remission and sustained disease control.

• Assessment of clinical activity of oral NX-13 versus placebo
• Evaluation of remission rates (MMS ≤ 2) after eight weeks of therapy
• Sub‑Study 2: Duvakitug efficacy in participants with active Crohn's disease
• Safety and tolerability profiling of investigational agents

Amicare’s multidisciplinary team leverages its expertise to advance therapeutic strategies that target immune‑mediated pathways in gastrointestinal disorders.